Contact
searchSearch
HMP Global
Login
Quiz

Atezolizumab Plus mFOLFOX for Patients With Mismatch Repair Deficient Colon Cancer

07/29/2025

Related Content

Midun Mala, MD
Videos
Evaluating Adjuvant HAI Pump Therapy in Patients With Resected Colorectal Liver Metastases
03/19/2026
Midhun Malla, MD, MS
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use...
03/19/2026
Oncology
News
HER2 Alterations Signal Poorer Outcomes in Untreated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
12/10/2025
Janelle Bradley
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF wild-type metastatic colorectal cancer, those who harbor HER2 alterations experience significantly worse survival but show no differential benefit from first-line anti-EGFR or bevacizumab therapy, according to an...
Among patients with RAS/BRAF...
12/10/2025
Oncology
News
Capecitabine Monotherapy for Elderly Patients With MRD-Negative High-Risk Colorectal Cancer
12/02/2025
Stephanie Holland
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy delivers survival outcomes comparable to capecitabine plus oxaliplatin while reducing the incidence of adverse events in elderly patients with MRD-negative high-risk colorectal cancer.
Capecitabine monotherapy...
12/02/2025
Oncology
News
Low-Dose Aspirin Significantly Reduces Recurrence in PI3K-Altered Localized Colorectal Cancer
11/24/2025
Stephanie Holland
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the ALASCCA trial, aspirin significantly reduced the risk of colorectal cancer recurrence among patients with PIK3CA hotspot mutations.
According to results from the...
11/24/2025
Oncology

Recent News

News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use